ecnoglutide has ~1,000 patients CV benefit : Semaglutide has proven 20% MACE reduction
Many patients are interested in Retatrutide because it may offer enhanced fat-loss support and broader metabolic benefits compared to earlier peptide therapies
Once inside the mitochondria, these fats are oxidizedor burnedto create usable energy
Most of the PIONEER trials indicated that oral semaglutide led to a 16 mmHg decrease in systolic blood pressure, and these reductions were statistically significant when comparing the effects of 14 mg oral semaglutide with those of a placebo [6,7,8,9, 12,13,14,15]
Ottaviani M, Alestas T, Flori E, Mastrofrancesco A, Zouboulis CC, Picardo M